Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 81

Sort by

Sort Order Select

Meeting Abstracts

757-P: Near-Normoglycemia and Insulin Regression Induced by Tirzepatide in Basal Insulin–Treated Type 2 Diabetes

JULIO ROSENSTOCK, SANTIAGO TOFE, CAROL H. WYSHAM, VIVIAN THIEU, JACEK I. KILJANSKI, CLARE LEE, HUI WANG, HIREN PATEL

Diabetes 2024;73(Supplement_1):757-P

https://doi.org/10.2337/db24-757-P

Published: 14 June 2024

View article titled, 757-P: Near-Normoglycemia and Insulin Regression Induced by Tirzepatide in Basal Insulin–Treated Type 2 Diabetes

Meeting Abstracts

743-P: Clinical Factors Associated with Insulin Regression When Adding Tirzepatide in Basal Insulin–Treated Type 2 Diabetes

CAROL H. WYSHAM, JULIO ROSENSTOCK, SANTIAGO TOFE, VIVIAN THIEU, JACEK I. KILJANSKI, CLARE LEE, HUI WANG, HIREN PATEL

Diabetes 2024;73(Supplement_1):743-P

https://doi.org/10.2337/db24-743-P

Published: 14 June 2024

View article titled, 743-P: Clinical Factors Associated with Insulin Regression When Adding Tirzepatide in Basal Insulin–Treated Type 2 Diabetes

Meeting Abstracts

229-OR: Orforglipron Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes

JULIO ROSENSTOCK, DEBORAH A. ROBINS, KEVIN L. DUFFIN, JONATHAN M. WILSON, KIEREN J. MATHER, HIYA BANERJEE, YANZHU LIN, SARAH EYDE, CHRISTOF M. KAZDA, MANIGE KONIG

Diabetes 2024;73(Supplement_1):229-OR

https://doi.org/10.2337/db24-229-OR

Published: 14 June 2024

View article titled, 229-OR: Orforglipron Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes

Meeting Abstracts

924-P: Impact of Sotagliflozin, a Dual Sodium–Glucose Cotransporter 1/2 Inhibitor, as Add-on to Inadequately Controlled Basal Insulin–Treated Type 2 Diabetes

JULIO ROSENSTOCK, AMY K. CARROLL, MARQUETTE B. HARDIN, PHILLIP L. BANKS, JOHN B. BUSE, MELANIE J. DAVIES, HARPREET S. BAJAJ, ANNE L. PETERS

Diabetes 2024;73(Supplement_1):924-P

https://doi.org/10.2337/db24-924-P

Published: 14 June 2024

View article titled, 924-P: Impact of Sotagliflozin, a Dual Sodium–Glucose Cotransporter 1/2 Inhibitor, as Add-on to Inadequately Controlled Basal Insulin–Treated Type 2 Diabetes

Meeting Abstracts

917-P: Sotagliflozin vs. Empagliflozin or Placebo in Type 2 Diabetes on a DPP-4i +/- Metformin

ANNE L. PETERS, MARQUETTE B. HARDIN, AMY K. CARROLL, PHILLIP L. BANKS, JULIO ROSENSTOCK

Diabetes 2024;73(Supplement_1):917-P

https://doi.org/10.2337/db24-917-P

Published: 14 June 2024

View article titled, 917-P: Sotagliflozin vs. Empagliflozin or Placebo in Type 2 Diabetes on a DPP-4i +/- Metformin

Meeting Abstracts

266-OR: Retatrutide, an Agonist of GIP, GLP-1, and Glucagon Receptors, Improves Markers of Pancreatic Beta-Cell Function and Insulin Sensitivity

JULIO ROSENSTOCK, TAMER COSKUN, MARK L. HARTMAN, JITONG LOU, QIWEI WU, YU DU, SIREL GURBUZ, KIEREN J. MATHER, ZVONKO MILICEVIC, MELISSA K. THOMAS

Diabetes 2024;73(Supplement_1):266-OR

https://doi.org/10.2337/db24-266-OR

Published: 14 June 2024

View article titled, 266-OR: Retatrutide, an Agonist of GIP, GLP-1, and Glucagon Receptors, Improves Markers of Pancreatic Beta-Cell Function and Insulin Sensitivity

Meeting Abstracts

179-OR: Improved A1C and TIR with Once-Weekly Insulin Icodec vs. Insulin Glargine U100 in Insulin-Naïve T2D—ONWARDS 1

JULIO ROSENSTOCK, STEPHEN C. BAIN, AMOOLYA GOWDA, HIROSHI HORIO, ESTEBAN JODAR, LARS LANG LEHRSKOV, ILDIKO LINGVAY, ROBERTO TREVISAN, OFRI MOSENZON

Diabetes 2023;72(Supplement_1):179-OR

https://doi.org/10.2337/db23-179-OR

Published: 24 June 2023

View article titled, 179-OR: Improved A1C and TIR with Once-Weekly Insulin Icodec vs. Insulin Glargine U100 in Insulin-Naïve T2D—ONWARDS 1

Meeting Abstracts

52-OR: Effect of Oral Nonpeptide GLP-1 Receptor Agonist Orforglipron (LY3502970) in Participants with Obesity or Overweight—A Phase 2 Study

SEAN WHARTON, THOMAS BLEVINS, LISA B. CONNERY, JULIO ROSENSTOCK, SOHINI RAHA, KIEREN J. MATHER, AXEL HAUPT, DEBORAH A. ROBINS, EDWARD J. PRATT, CHRISTOF M. KAZDA, MANIGE KONIG

Diabetes 2023;72(Supplement_1):52-OR

https://doi.org/10.2337/db23-52-OR

Published: 23 June 2023

View article titled, 52-OR: Effect of Oral Nonpeptide GLP-1 Receptor Agonist Orforglipron (LY3502970) in Participants with Obesity or Overweight—A Phase 2 Study

Meeting Abstracts

775-P: Predictors of Glycemic Control in Older People with Type 2 Diabetes Treated with iGlarLixi—A Pooled Analysis

MEDHA MUNSHI, ROBERT RITZEL, RORY J. MCCRIMMON, IRENE HRAMIAK, FELIPE LAUAND, LYDIE MELAS-MELT, ELISABETH SOUHAMI, JULIO ROSENSTOCK

Diabetes 2023;72(Supplement_1):775-P

https://doi.org/10.2337/db23-775-P

Published: 20 June 2023

View article titled, 775-P: Predictors of Glycemic Control in Older People with Type 2 Diabetes Treated with iGlarLixi—A Pooled Analysis

Meeting Abstracts

773-P: Consistent Glycemic Efficacy and Safety of Concomitant Use of iGlarLixi and Sodium–Glucose Cotransporter-2 Inhibitor Therapy for Type 2 Diabetes—A Patient-Level Pooled Analysis

FRANCESCO GIORGINO, CRISTIAN GUJA, MELANIE J. DAVIES, HASAN AYDIN, FELIPE LAUAND, ELISABETH SOUHAMI, LYDIE MELAS-MELT, VANITA R. ARODA, JULIO ROSENSTOCK

Diabetes 2023;72(Supplement_1):773-P

https://doi.org/10.2337/db23-773-P

Published: 20 June 2023

View article titled, 773-P: Consistent Glycemic Efficacy and Safety of Concomitant Use of iGlarLixi and Sodium–Glucose Cotransporter-2 Inhibitor Therapy for Type 2 Diabetes—A Patient-Level Pooled Analysis

Meeting Abstracts

788-P: Predictors of Achieving Target HbA1c <7% in People with Type 2 Diabetes Advancing Treatment with iGlarLixi

ALICE Y. CHENG, JUAN P. FRIAS, CRISTIAN GUJA, FELIPE LAUAND, LYDIE MELAS-MELT, AGUSTINA ALVAREZ, ELISABETH SOUHAMI, JULIO ROSENSTOCK

Diabetes 2023;72(Supplement_1):788-P

https://doi.org/10.2337/db23-788-P

Published: 20 June 2023

View article titled, 788-P: Predictors of Achieving Target HbA1c <7% in People with Type 2 Diabetes Advancing Treatment with iGlarLixi

Meeting Abstracts

1238-P: The Face of Diabetic Cardiomyopathy—Baseline Characteristics from the ARISE-HF Trial

JAVED BUTLER, STEFANO DEL PRATO, JUSTIN EZEKOWITZ, NASRIEN E. IBRAHIM, CAROLYN S. LAM, RICCARDO PERFETTI, JULIO ROSENSTOCK, W.H. WILSON TANG, ALESSIA URBINATI, FAIEZ ZANNAD, JAMES L. JANUZZI

Diabetes 2023;72(Supplement_1):1238-P

https://doi.org/10.2337/db23-1238-P

Published: 20 June 2023

View article titled, 1238-P: The Face of Diabetic Cardiomyopathy—Baseline Characteristics from the ARISE-HF Trial

Meeting Abstracts

800-P: Predictors of HbA1c and dTIR Responses with iGlarLixi in Type 2 Diabetes—Patient-Level Exploratory Analyses of the LixiLan-L Trial

MARTIN HALUZIK, JUAN P. FRIAS, ALICE Y. CHENG, MOHAMMED AL-SOFIANI, FELIPE LAUAND, LYDIE MELAS-MELT, ELISABETH SOUHAMI, JULIO ROSENSTOCK

Diabetes 2023;72(Supplement_1):800-P

https://doi.org/10.2337/db23-800-P

Published: 20 June 2023

View article titled, 800-P: Predictors of HbA1c and dTIR Responses with iGlarLixi in Type 2 Diabetes—Patient-Level Exploratory Analyses of the LixiLan-L Trial

Meeting Abstracts

799-P: Predictors of Glycemic Control by Derived Time in Range for People with Type 2 Diabetes Advancing with iGlarLixi—A Pooled Analysis

IRENE HRAMIAK, JUAN P. FRIAS, HASAN AYDIN, FELIPE LAUAND, LYDIE MELAS-MELT, ELISABETH SOUHAMI, MARTIN HALUZIK, JULIO ROSENSTOCK

Diabetes 2023;72(Supplement_1):799-P

https://doi.org/10.2337/db23-799-P

Published: 20 June 2023

View article titled, 799-P: Predictors of Glycemic Control by Derived Time in Range for People with Type 2 Diabetes Advancing with iGlarLixi—A Pooled Analysis

Meeting Abstracts

751-P: Longer Time Spent in Glycemic Control after Initiating Tirzepatide vs. Comparators—Exploratory Analysis of SURPASS 1–5 Trials

JULIO ROSENSTOCK, W. TIMOTHY GARVEY, RACHEL L. BATTERHAM, MINZHI LIU, BRANDON BERGMAN, ANDREA HEMMINGWAY, VIVIAN THIEU

Diabetes 2023;72(Supplement_1):751-P

https://doi.org/10.2337/db23-751-P

Published: 20 June 2023

View article titled, 751-P: Longer Time Spent in Glycemic Control after Initiating Tirzepatide vs. Comparators—Exploratory Analysis of SURPASS 1–5 Trials

Meeting Abstracts

750-P: “SURPASS(ing)” an Era of Basal-Bolus Insulin Therapy—Tirzepatide vs. Insulin Lispro TID Added-on to Poorly Controlled Basal Insulin-Treated in Type 2 Diabetes

JULIO ROSENSTOCK, JUAN P. FRIAS, HELENA W. RODBARD, SANTIAGO TOFE, EMMALEE J. SEARS, RUTH HUH, LAURA FERNANDEZ LANDO, HIREN PATEL

Diabetes 2023;72(Supplement_1):750-P

https://doi.org/10.2337/db23-750-P

Published: 20 June 2023

View article titled, 750-P: “SURPASS(ing)” an Era of Basal-Bolus Insulin Therapy—Tirzepatide vs. Insulin Lispro TID Added-on to Poorly Controlled Basal Insulin-Treated in Type 2 Diabetes

Meeting Abstracts

747-P: Duration of Sustained Weight Loss in Clinical Trials Evaluating Tirzepatide vs. Comparators—An Exploratory Analysis of SURPASS 1–5

W. TIMOTHY GARVEY, RACHEL L. BATTERHAM, JULIO ROSENSTOCK, MINZHI LIU, VIVIAN THIEU, JACK DALY, BRANDON BERGMAN

Diabetes 2023;72(Supplement_1):747-P

https://doi.org/10.2337/db23-747-P

Published: 20 June 2023

View article titled, 747-P: Duration of Sustained Weight Loss in Clinical Trials Evaluating Tirzepatide vs. Comparators—An Exploratory Analysis of SURPASS 1–5

Meeting Abstracts

450-P: N-Terminal Pro-B Type Natriuretic Peptide Concentrations in Diabetic Cardiomyopathy—Baseline Data from the ARISE-HF Trial

JAVED BUTLER, STEFANO DEL PRATO, JUSTIN EZEKOWITZ, NASRIEN E. IBRAHIM, CAROLYN S. LAM, RICCARDO PERFETTI, JULIO ROSENSTOCK, W.H. WILSON TANG, ALESSIA URBINATI, FAIEZ ZANNAD, JAMES L. JANUZZI, JR.

Diabetes 2023;72(Supplement_1):450-P

https://doi.org/10.2337/db23-450-P

Published: 20 June 2023

View article titled, 450-P: N-Terminal Pro-B Type Natriuretic Peptide Concentrations in Diabetic Cardiomyopathy—Baseline Data from the ARISE-HF Trial

Meeting Abstracts

85-LB: CGM Outcomes and Hypoglycemia Duration with Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 in Insulin-Naïve T2D—ONWARDS 1 Exploratory Analysis

RICHARD M. BERGENSTAL, SARA K. WATT, ANA LAURA S.A. MATOS, ILDIKO LINGVAY, JULIA K. MADER, TOMOYUKI NISHIDA, JULIO ROSENSTOCK

Diabetes 2023;72(Supplement_1):85-LB

https://doi.org/10.2337/db23-85-LB

Published: 20 June 2023

View article titled, 85-LB: CGM Outcomes and Hypoglycemia Duration with Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 in Insulin-Naïve T2D—ONWARDS 1 Exploratory Analysis

Meeting Abstracts

833-P: Impact of Hypoglycemia on Insulin Titration and Fasting Plasma Glucose in Basal Insulin–Treated Type 2 Diabetes: A Subanalysis of the SoliMix Trial

FRANCESCO GIORGINO, JULIO ROSENSTOCK, ROBERT RITZEL, OGUZHAN DEYNELI, AGUSTINA ALVAREZ, ELISABETH SOUHAMI, LYDIE MELAS-MELT, RORY J. MCCRIMMON

Diabetes 2022;71(Supplement_1):833-P

https://doi.org/10.2337/db22-833-P

Published: 01 June 2022

View article titled, 833-P: Impact of Hypoglycemia on Insulin Titration and Fasting Plasma Glucose in Basal Insulin–Treated Type 2 Diabetes: A Subanalysis of the SoliMix Trial

NARROW

757-P: Near-Normoglycemia and Insulin Regression Induced by Tirzepatide in Basal Insulin–Treated Type 2 Diabetes

743-P: Clinical Factors Associated with Insulin Regression When Adding Tirzepatide in Basal Insulin–Treated Type 2 Diabetes

229-OR: Orforglipron Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes

924-P: Impact of Sotagliflozin, a Dual Sodium–Glucose Cotransporter 1/2 Inhibitor, as Add-on to Inadequately Controlled Basal Insulin–Treated Type 2 Diabetes

917-P: Sotagliflozin vs. Empagliflozin or Placebo in Type 2 Diabetes on a DPP-4i +/- Metformin

266-OR: Retatrutide, an Agonist of GIP, GLP-1, and Glucagon Receptors, Improves Markers of Pancreatic Beta-Cell Function and Insulin Sensitivity

179-OR: Improved A1C and TIR with Once-Weekly Insulin Icodec vs. Insulin Glargine U100 in Insulin-Naïve T2D—ONWARDS 1

52-OR: Effect of Oral Nonpeptide GLP-1 Receptor Agonist Orforglipron (LY3502970) in Participants with Obesity or Overweight—A Phase 2 Study

775-P: Predictors of Glycemic Control in Older People with Type 2 Diabetes Treated with iGlarLixi—A Pooled Analysis

773-P: Consistent Glycemic Efficacy and Safety of Concomitant Use of iGlarLixi and Sodium–Glucose Cotransporter-2 Inhibitor Therapy for Type 2 Diabetes—A Patient-Level Pooled Analysis

788-P: Predictors of Achieving Target HbA1c <7% in People with Type 2 Diabetes Advancing Treatment with iGlarLixi

1238-P: The Face of Diabetic Cardiomyopathy—Baseline Characteristics from the ARISE-HF Trial

800-P: Predictors of HbA1c and dTIR Responses with iGlarLixi in Type 2 Diabetes—Patient-Level Exploratory Analyses of the LixiLan-L Trial

799-P: Predictors of Glycemic Control by Derived Time in Range for People with Type 2 Diabetes Advancing with iGlarLixi—A Pooled Analysis

751-P: Longer Time Spent in Glycemic Control after Initiating Tirzepatide vs. Comparators—Exploratory Analysis of SURPASS 1–5 Trials

750-P: “SURPASS(ing)” an Era of Basal-Bolus Insulin Therapy—Tirzepatide vs. Insulin Lispro TID Added-on to Poorly Controlled Basal Insulin-Treated in Type 2 Diabetes

747-P: Duration of Sustained Weight Loss in Clinical Trials Evaluating Tirzepatide vs. Comparators—An Exploratory Analysis of SURPASS 1–5

450-P: N-Terminal Pro-B Type Natriuretic Peptide Concentrations in Diabetic Cardiomyopathy—Baseline Data from the ARISE-HF Trial

85-LB: CGM Outcomes and Hypoglycemia Duration with Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 in Insulin-Naïve T2D—ONWARDS 1 Exploratory Analysis

833-P: Impact of Hypoglycemia on Insulin Titration and Fasting Plasma Glucose in Basal Insulin–Treated Type 2 Diabetes: A Subanalysis of the SoliMix Trial

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only